Search Results - "Paczuski, Pawel"

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s

    Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s by McComsey, Grace A., Moser, Carlee, Currier, Judith, Ribaudo, Heather J., Paczuski, Pawel, Dubé, Michael P., Kelesidis, Theodoros, Rothenberg, Jennifer, Stein, James H., Brown, Todd T.

    Published in Clinical infectious diseases (01-04-2016)
    “…Background. Fat gain after antiretroviral therapy (ART) occurs, and its association with protease inhibitors (PIs) is unclear. Methods. Peripheral and central…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    High Baseline Anal Human Papillomavirus and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus–Infected Individuals Older Than 26 Years: ACTG 5298

    High Baseline Anal Human Papillomavirus and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus–Infected Individuals Older Than 26 Years: ACTG 5298 by Cranston, Ross D, Cespedes, Michelle S, Paczuski, Pawel, Yang, Ming, Coombs, Robert W, Dragavon, Joan, Saah, Alfred, Godfrey, Catherine, Webster-Cyriaque, Jennifer Y, Chiao, Elizabeth Y, Bastow, Barbara, Wilkin, Timothy

    Published in Sexually transmitted diseases (01-04-2018)
    “…BACKGROUNDThe quadrivalent human papillomavirus (HPV) vaccine (qHPV; types 6, 11, 16, 18) is indicated for men and women aged 9 to 26 years to prevent HPV…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  3. 3
    High Baseline Anal HPV and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent HPV Vaccine in HIV-infected individuals over 26 years old: ACTG 5298

    High Baseline Anal HPV and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent HPV Vaccine in HIV-infected individuals over 26 years old: ACTG 5298 by Cranston, Ross D., Cespedes, Michelle S., Paczuski, Pawel, Yang, Ming, Coombs, Robert W., Dragavon, Joan, Saah, Alfred, Godfrey, Catherine, Webster-Cyriaque, Jennifer Y., Chiao, Elizabeth Y, Bastow, Barbara, Wilkin, Timothy

    Published in Sexually transmitted diseases (01-04-2018)
    Get full text
    Journal Article
    Save to List
    Saved in:
  4. 4
    High Baseline Anal HPV and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent HPV Vaccine in HIV-infected individuals over 26 years old: ACTG 5298

    High Baseline Anal HPV and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent HPV Vaccine in HIV-infected individuals over 26 years old: ACTG 5298 by Cranston, Ross D, Cespedes, Michelle S, Paczuski, Pawel, Yang, Ming, Coombs, Robert W, Dragavon, Joan, Saah, Alfred, Godfrey, Catherine, Webster-Cyriaque, Jennifer Y, Chiao, Elizabeth Y, Bastow, Barbara, Wilkin, Timothy

    Published in Sexually transmitted diseases (13-10-2017)
    “…BACKGROUNDThe quadrivalent human papillomavirus (HPV) vaccine (qHPV; types 6, 11, 16, 18) is indicated for men and women 9-26 years to prevent HPV associated…”
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: